SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
YS Biopharma Co., Ltd. (YS) , forward earnings yield 99.01%.
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
- Forward P/E 1.0
Overall SharesGrow Score: 27/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — YS
Valuation Multiples
P/E (TTM)0.0
Forward P/E1.0
PEG RatioN/A
Forward PEG0.00
P/B Ratio0.00
P/S Ratio0.18
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.94
Forward EPS (Est.)$1.01
Book Value / Share$0.00
Revenue / Share$5.75
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield99.01%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2021 |
$-2.08 |
$257.02M |
$-191.83M |
-74.6% |
| 2022 |
$-1.15 |
$502.95M |
$-106M |
-21.1% |
| 2023 |
$-1.56 |
$687.2M |
$-145.48M |
-21.2% |
| 2024 |
$-4.05 |
$573.42M |
$-433.46M |
-75.6% |
| 2025 |
$-0.94 |
$614.96M |
$-99.98M |
-16.3% |
